Cases & Deals

Sanofi and Janssen collaborate to develop vaccines for extra-intestinal pathogenic E. coli

Client(s) Sanofi

Jones Day represented and supported Sanofi's in-house team in its strategic collaboration with Janssen Pharmaceuticals, now “Johnson & Johnson Innovative Medicine," in connection with a Co-Development, Co-Commercialization & License Agreement with Johnson & Johnson's Janssen Pharmaceuticals relating to the development and commercialization of vaccines for extra-intestinal pathogenic E. coli. Both parties will co-fund current and future research and development costs, followed by development and commercial milestones. Sanofi will share profits in the U.S., France, Germany, Italy, Spain, and the UK; and Janssen will receive tiered royalties and sales milestones in the rest of world.